Antje Margret Wengner

USPTO Granted Patents = 29 (Patent Applications = 28)

CIPO Patents = 3 (Patent Applications = 9)

EPO Patents = 23 (Patent Applications = 44)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 48(Granted Patents)

Company Filing History:

23 out of 378

Bayer Pharma Aktiengesellschaft

patents

8 out of 721

Bayer Intellectual Property Gmbh

patents

4 out of 12,157

Bayer Aktiengesellschaft

patents

4. 3 out of 443

The Broad Institute, Inc.

patents

5. 3 out of 1,206

Dana-farber-cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12053476 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2024-08-06),

2. 11976334 - Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease (2024-05-07),

3. 11712440 - Predictive markers for ATR kinase inhibitors (2023-08-01),

4. 11690911 - Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors (2023-07-04),

5. 11660301 - Combination of ATR kinase inhibitors with PARP inhibitors (2023-05-30),

6. 11529356 - 2-(morpholin-4-yl)-1,7-naphthyridines (2022-12-20),

7. 11142522 - Compounds, compositions and methods for cancer treatment (2021-10-12),

8. 10966986 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2021-04-06),

9. 10894784 - Heteroarylbenzimidazole compounds (2021-01-19),

10. 10772893 - 2-(morpholin-4-yl)-1,7-naphthyridines (2020-09-15),

11. 10729680 - 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines (2020-08-04),

12. 10604532 - Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases (2020-03-31),

13. 10266548 - Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases (2019-04-23),

14. 10226469 - Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas (2019-03-12),

15. 10214545 - Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders (2019-02-26),

Title: Antje Margret Wengner: Innovator in Cancer Treatment and Patient Stratification

Introduction: Antje Margret Wengner is a distinguished inventor based in Berlin, Germany, known for her significant contributions to the field of cancer research. With an impressive portfolio of 29 patents, Dr. Wengner has been instrumental in developing innovative solutions that enhance patient outcomes in oncology.

Latest Patents: Among her noteworthy inventions, two recent patents stand out. The first patent, titled "Compounds, compositions and methods for cancer patient stratification and cancer treatment," focuses on improved compounds that utilize biomarkers such as PDE3A, SLFN12, and CREB3L1. These biomarkers correlate with drug sensitivity, allowing for a more stratified approach to treating cancer patients. The second patent, "Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease," introduces a compound known as Compound A. This invention is designed for the treatment of hyper-proliferative diseases, presenting a method for determining patient responsiveness based on specific biomarkers.

Career Highlights: Antje Wengner has collaborated with prominent organizations, notably Bayer Pharma AG and Bayer Intellectual Property GmbH. Her work has positioned her at the forefront of pharmaceutical innovation, particularly in treatments that target cancer and other hyper-proliferative diseases.

Collaborations: Dr. Wengner's innovative journey has been enriched by collaborations with esteemed colleagues such as Gerhard Siemeister and Philip Lienau. These partnerships have fostered a creative environment that promotes the advancement of groundbreaking medical solutions.

Conclusion: Antje Margret Wengner is a leading figure in the realm of cancer treatment innovation. Her extensive patent portfolio and research contributions reflect a commitment to improving patient care through enhanced stratification and treatment methods. With a solid background in collaborations and a focus on biomarker identification, Dr. Wengner continues to pave the way for future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.